



EAU27

AMSTERDAM
The Netherlands
19-22 March 2027

Cutting-edge Science at Europe's largest Urology Congress

Abstract submission deadline

1 November 2026 at 23:59 Central European Time (CET)

- To avoid technical issues, submit well before the deadline.
- Use Google Chrome (latest version) for submitting your abstract.
- Edit and withdrawal: Until the deadline, authors can make changes or withdraw abstracts via the submission system. Withdrawal after the deadline requires an email to abstracts@congressconsultants.com before 19 January 2027.

Rules & regulations related to presentation and publication of abstracts

- Encore abstracts are not accepted—submissions must not have been published or presented before the EAU27 Congress.
- All financial support, such as government grants or involvement from companies in data handling, must be declared in the designated submission field—not in the abstract text. All funding sources and abbreviations should be fully spelled out. This information will be published alongside your abstract in all EAU publications and online platforms.
- At least one author or a designated representative must confirm their presentation and register for the congress by **19 January**. The abstract must be delivered on-site in Amsterdam. Failure to confirm participation and register by the deadline may result in the abstract being removed from the programme.
- If no presenter is available during the scheduled session, despite having confirmed participation, this will be considered as a no show and will result in the abstract being removed from the programme and no presentation certificate will be issued.
- Publication in the European Urology Journal Supplement requires presentation at the congress. Only accepted abstracts that are presented in Amsterdam will be eligible for publication after the congress.
- Accepted abstracts, videos, and author lists will be published as submitted, with only basic English spelling corrections.

Copyright

- All accepted abstracts, including any figures and tables, become the property of the European Association of Urology (EAU) and are protected by copyright. This ownership also extends to **all materials derived from the abstract**, such as posters, videos, slide or audio presentations, live-streams, webcasts, and any other related content.
- By submitting an abstract, you (and your co-authors) agree to these terms. Any copyright conflicts with other scientific associations are the responsibility of the author(s).
- Requests to reuse any material can be sent to abstracts@congressconsultants.com (please include the abstract code).
- Copyright may be temporarily shared with companies for up to one year upon written request to sales@uroweb.org, subject to a fee.



Content related instructions

All abstracts must be submitted in **English**.

Ethical approval and human experimentation

In clinical studies, the authors must state that an Ethical Committee approval has been obtained.

Please note that the statement should clearly indicate whether the approval was obtained or not, accompanied by a brief explanation of the reason in case of a disapproval. This information is necessary for the proper processing of the review. Any human experimentation conducted with respect to the submitted abstract(s), should have been conducted according to the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the works should have been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association. Council may enquire further into ethical aspects when evaluating the abstract(s).

Case reports

Only high-quality case reports accompanied by a systematic literature review, which is based on a clearly defined protocol, are allowed. Other case reports are not eligible for submission and/or subject to desk reject.

Systematic reviews

Systematic reviews (with or without meta-analysis) can be submitted only when they meet the following standards:

- The clinical question studied is highly relevant to current practice and/or practice changing
- The clinical question was clearly defined using a standard PICO format
- A comprehensive systematic literature search was carried out
- An assessment of the risk of bias was made
- Key findings are clearly described including clinical practice relevance

Trial in progress

Trials in progress abstracts offer researchers a platform to present ongoing trials, promote collaboration, and discuss correlatives and innovative trial designs. It is expected that abstracts submitted as trial in progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Trial in progress abstracts should contain the following two sections and should not have data analysis available before the submission deadline.

- **Introduction and objectives**
Provide the scientific background and rationale of the trial, highlighting correlative studies of interest.
- **Materials and methods**
Detail the trial design and statistical methods, emphasizing any innovative aspects.
Outline the planned interventions and specify major eligibility criteria.
Report current enrolment without disclosing protocol-specified results.
State clinical trial registry number.

Topic

A topic must be selected for your submission, the system will offer you a drop-down menu. For the review of the abstract, it is of vital importance that the correct (sub)topic, clinical step(s) and management tool(s) are selected.



EAU27

AMSTERDAM
The Netherlands
19-22 March 2027

Cutting-edge Science at Europe's largest Urology Congress

Abstract size

The size of the abstract is limited to 3,000 characters (this includes title, body of abstract, spaces, tables and pictures/graphics). The submission programme will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements. A picture/graphic counts for 500 characters.

Authors and affiliations

- A maximum of 24 authors per abstract is allowed.
- Each quoted author should have contributed substantially to the represented work in terms of conceptual design or analysis, writing of the article and final approval of the article in order to take public responsibility for the content.
- An abstract presenter is limited to 5 abstract presentations.
- Presenting authors can be changed upon acceptance.
- Please make sure to write the name of the Organisation/Institution, Department, City and Country in English (one institution per author).
- If co-authors are from the same institution, the programme will automatically copy all information into the next boxes, so you do not have to type all information again. If co-authors are not from the same institution, you can edit any box as your wish.

Proof reading

After entering all required information, a preview of your abstract will appear on screen. Please review it carefully, including the author details, to ensure everything is accurate.

Once you click submit, a PDF copy of your abstract will be sent to you by email. Be sure to save this PDF for your records. It is the responsibility of the submitting author to ensure the abstract is complete and free of spelling or grammatical errors. No corrections or revisions will be accepted after submission.

Presenting in abstract sessions

Presenting authors are expected to attend their abstract session in person to discuss their research.

If selected, presenters will be required to prepare and upload additional abstract materials before the congress. Detailed instructions will be provided upon acceptance.

Format of presentations at EAU27

There are three types of presentations at the congress: oral, expert-guided poster tour, and video. For submission purposes, the criteria for oral and poster tour presentations are the same. Therefore, please select 'poster' when submitting your abstract. The Scientific Congress Office will determine the final presentation format (oral or expert-guided poster tour) in December. Detailed instructions will be provided after the selection process is complete.

AI technology

Where authors use generative AI and AI-assisted technologies in the writing process, these technologies should only be used to improve readability and language of the work. Applying the technology should be done with human oversight and control and authors should carefully review and edit the result, because AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. The authors are ultimately responsible and accountable for the contents of the work. Authors should disclose in their abstract the use of AI and AI-assisted technologies. A disclosure question will appear as a pop-up at the end of the submission process.

Authors should not list AI and AI-assisted technologies as an author or co-author, nor cite AI as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans. Authors are also responsible for ensuring that the work is original.



Abstract review process and outcome

All abstracts are subject to peer review and are expected to meet the standards of academic/scientific excellence. Submissions will be reviewed by an expert panel whose identities will remain anonymous to the authors. Reviewers will give scores from 1 to 5 points, taking into consideration the following criteria: Originality, priority, quality of research methodology and data. Review and session composition will take place in November/December 2026.

The outcome of the abstract selection is available online through the abstract submission website on 21 December 2026. You will receive notification by email. The Scientific Congress Office reserves the right to obtain your raw data for statistical evaluation.

Technical instructions

Technical instructions on how to navigate the submission page are available on the right side of the screen under the **Help** tab.

Late-breaking abstract submission

Late-breaking abstracts are intended for high-impact research that was not complete or available by the regular submission deadline. Submissions must present novel, time-sensitive data of major scientific importance — such as results from pivotal clinical trials or breakthrough studies — that could not have been submitted or presented earlier. Late-breaking abstracts are subject to stricter selection criteria and must include robust, final data at the time of submission. Preliminary or incomplete data will not be accepted.

Only abstracts that meet these standards will be considered for late-breaking presentation.

Placeholder

Authors intending to submit a late-breaking abstract are required to submit a placeholder abstract by the regular abstract submission deadline. This placeholder must include a provisional title, author list, and a brief description of the study's objective or rationale. Final data must be submitted during the official late-breaking submission period.

Standalone Placeholder submissions for late-breakers is available via the [online submission system](#).

Please note the following important conditions:

- Submissions that do not meet the criteria for late-breaking abstracts will be automatically rejected.
- Abstracts intended for regular submission but mistakenly submitted under the Late-breaker category will not be transferred and will be rejected.
- Placeholder submission is done at the author's own risk. Acceptance is not guaranteed, regardless of placeholder submission.
- The Scientific Committee will not respond to claims or disputes related to the acceptance or rejection of placeholder submissions.

The placeholder does not require final data but must clearly indicate the intent to submit a late-breaking abstract by answering the designated question box when selecting 'Late-breaking' at the end of the submission.



EAU27

AMSTERDAM
The Netherlands
19-22 March 2027

Cutting-edge Science at Europe's largest Urology Congress

The late-breaking submission period opens **on 21 December 2026**. The final, updated late-breaking data must be submitted by **23 January 2027, 23:59 CET** — the late-breaking deadline. Abstracts without updated data will not be considered.

For any questions, please contact the Abstract Handling Department at abstracts@congressconsultants.com